Published in Antisense Nucleic Acid Drug Dev on August 01, 1998
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A (2000) 3.04
DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J (2005) 2.03
Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res (2001) 1.67
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature (2011) 1.41
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today (2008) 1.37
2'-Deoxy-2'-fluoro-beta-D-arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. Nucleic Acids Res (2000) 1.23
siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12
Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A (1999) 1.09
Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells. Mol Ther Nucleic Acids (2015) 0.84
Thermodynamic analysis of nylon nucleic acids. Chembiochem (2008) 0.83
Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. Skelet Muscle (2011) 0.82
Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations. Nucleic Acid Ther (2012) 0.76
Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are? World J Gastroenterol (2014) 0.75
A one-step solid phase extraction method for bioanalysis of a phosphorothioate oligonucleotide and its 3' n-1 metabolite from rat plasma by uHPLC-MS/MS. AAPS J (2012) 0.75
DNA as therapeutics; an update. Indian J Pharm Sci (2009) 0.75
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. Mol Cell Biol (1994) 3.27
Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J Biol Chem (2000) 2.88
Copper metallothionein of yeast, structure of the gene, and regulation of expression. Proc Natl Acad Sci U S A (1984) 2.74
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry (1989) 2.26
Mitomycin C: a review. Cancer Treat Rev (1976) 1.92
Chemical synthesis and expression of a cassette adapted ubiquitin gene. J Biol Chem (1987) 1.84
Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature (1988) 1.68
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev (1979) 1.60
Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A (1989) 1.58
Properties of cloned and expressed human RNase H1. J Biol Chem (1999) 1.52
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J (1988) 1.42
Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res (1992) 1.39
Comprehensive reform of the new drug regulatory process. Biotechnology (N Y) (1995) 1.38
Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL-1 cells. Mol Pharmacol (1988) 1.35
Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli. Proc Natl Acad Sci U S A (1989) 1.30
Cloning and expression of a yeast copper metallothionein gene. Gene (1984) 1.30
Yeast metallothionein function in metal ion detoxification. J Biol Chem (1986) 1.28
Bleomycin, a review. J Med (1976) 1.26
Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. J Biol Chem (1987) 1.26
Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry (1997) 1.23
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther (1998) 1.20
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res (1982) 1.18
Leukotriene D4 treatment of bovine aortic endothelial cells and murine smooth muscle cells in culture results in an increase in phospholipase A2 activity. J Biol Chem (1986) 1.17
Ubiquitin-metallothionein fusion protein expression in yeast. A genetic approach for analysis of ubiquitin functions. J Biol Chem (1988) 1.15
Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J Biol Chem (1997) 1.15
Cloning of a phospholipase A2-activating protein. Proc Natl Acad Sci U S A (1991) 1.13
Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities. Mol Pharmacol (1986) 1.11
Investigating the structure of human RNase H1 by site-directed mutagenesis. J Biol Chem (2001) 1.09
Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep (1980) 1.09
Purification and characterization of a phosphoinositide-specific phospholipase C from guinea pig uterus. Phosphorylation by protein kinase C in vivo. J Biol Chem (1987) 1.09
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res (1987) 1.09
Gene synthesis, expression, and processing of human ubiquitin carboxyl extension proteins. J Biol Chem (1989) 1.07
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res (1985) 1.07
Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc Natl Acad Sci U S A (1999) 1.07
Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res (1979) 1.05
Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. Mol Pharmacol (1987) 1.02
Interactions of 5-lipoxygenase with membranes: studies on the association of soluble enzyme with membranes and alterations in enzyme activity. Biochemistry (1988) 1.02
Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line. Life Sci (1986) 1.01
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des (1997) 1.01
Effect of leukotrienes, bradykinin and calcium ionophore (A 23187) on bovine endothelial cells: release of prostacyclin. Prostaglandins (1986) 1.00
Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells. Proc Natl Acad Sci U S A (1986) 1.00
Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: mechanism of signal transduction for leukotriene-D4 receptors. Mol Pharmacol (1987) 0.99
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J Med Chem (1987) 0.99
Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. J Biol Chem (1988) 0.98
Peptidoleukotrienes: distinct receptors for leukotriene C4 and D4 in the guinea-pig lung. Biochem Biophys Res Commun (1983) 0.98
In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther (1995) 0.97
Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res (1982) 0.96
In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res (1986) 0.95
Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Res (1983) 0.94
The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J Biol Chem (1997) 0.94
Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol (2001) 0.94
Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo. J Lab Clin Med (1990) 0.94
A spectroscopic investigation of the metal binding site of bleomycin A2. The Cu(II) and Zn(II) derivatives. Biochim Biophys Acta (1978) 0.94
Etoposide (VP-16-213). Cancer Treat Rev (1979) 0.93
Expression and accurate processing of yeast penta-ubiquitin in Escherichia coli. J Biol Chem (1987) 0.93
Combinatorial drug discovery: which methods will produce the greatest value? Biotechnology (N Y) (1995) 0.92
Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem (1998) 0.92
Bifunctional intercalation of antitumor antibiotics BBM-928A and echinomycin with deoxyribonucleic acid. Effects of intercalation on deoxyribonucleic acid degradative activity of bleomycin and phleomycin. Biochemistry (1982) 0.92
Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. Biochem J (1993) 0.92
Differential effects of fluoride on adenylate cyclase activity and guanine nucleotide regulation of agonist high-affinity receptor binding. Biochem J (1988) 0.92
Phorbol ester-mediated inhibition of vasopressin and beta-adrenergic responses in a vascular smooth muscle cell line. Mol Pharmacol (1987) 0.91
SKF 104353, a high affinity antagonist for human and guinea pig lung leukotriene D4 receptor, blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D4. Mol Pharmacol (1987) 0.91
Interactions of a new antitumor antibiotic BBM-928A with deoxyribonucleic acid. Bifunctional intercalative binding studied by fluorometry and viscometry. Biochemistry (1980) 0.91
Quantitative measurement of single- and double-strand breakage of DNA in Escherichia coli by the antitumor antibiotics bleomycin and talisomycin. Antimicrob Agents Chemother (1985) 0.91
Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J Med Chem (1986) 0.91
Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells. J Biol Chem (1987) 0.91
Ubiquitin function studied by disulfide engineering. J Biol Chem (1989) 0.91
DNA supercoiling, shortening, and induction of single-strand regions by cis-diamminedichloroplatinum(II). Cancer Res (1981) 0.90
In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des (1991) 0.90
Leukotriene D4 receptor-mediated hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth muscle cells. J Pharmacol Exp Ther (1988) 0.90
Progress in evaluation of the potential of antisense technology. Antisense Res Dev (1994) 0.90
Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol Pharmacol (1995) 0.90
The cellular pharmacology of auranofin. Semin Arthritis Rheum (1987) 0.90
Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure--activity relationships of marcellomycin and its analogues as compared to adriamycin. Biochemistry (1979) 0.89
Molecular cloning and expression of cDNA for human RNase H. Antisense Nucleic Acid Drug Dev (1998) 0.89
Identification and characterization of vascular (V1) vasopressin receptors of an established smooth muscle cell line. Mol Pharmacol (1987) 0.89
Maytansine. Cancer Treat Rev (1978) 0.89
Leukotriene D4 receptor-mediated synthesis and release of arachidonic acid metabolites in guinea pig lung: induction of thromboxane and prostacyclin biosynthesis by leukotriene D4. J Pharmacol Exp Ther (1986) 0.88
Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. Biochemistry (1981) 0.87
Human RNases H. Methods Enzymol (2001) 0.87
Identification of specific binding sites for leukotriene C4 in human fetal lung. Prostaglandins (1984) 0.87
The binding of leukotriene C4 and leukotriene D4 to membranes of a smooth muscle cell line (BC3H1) and evidence that leukotriene induced contraction in these cells is mediated by thromboxane, protein and RNA syntheses. Eur J Pharmacol (1985) 0.87
Viscometric and fluorometric studies of deoxyribonucleic acid interactions of several new anthracyclines. Biochemistry (1982) 0.87
Comparison of DNA damage and single- and double-strand breakage activities on PM-2 DNA by talisomycin and bleomycin analogs. Cancer Res (1980) 0.87
Multiple (alpha-NH-ubiquitin)protein endoproteases in cells. J Biol Chem (1989) 0.86
Inhibition of phosphoinositide-specific phospholipase C by manoalide. Mol Pharmacol (1987) 0.86
Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation. J Pharmacol Exp Ther (1986) 0.86
Comparison of the sequences at specific sites on DNA cleaved by the antitumor antibiotics talisomycin and bleomycin. Cancer Res (1982) 0.86
Regulation of ligand binding to leukotriene D4 receptors: effects of cations and guanine nucleotides. Eur J Pharmacol (1984) 0.86
Application of a tissue culture microtiter test for the detection of cytotoxic agents from natural products. J Antibiot (Tokyo) (1985) 0.85
Interactions of bleomycin analogues with deoxyribonucleic acid and metal ions studied by fluorescence quenching. Biochemistry (1980) 0.85
Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem Pharmacol (1986) 0.85
Low-molecular-weight nuclear RNAs. Perspect Biol Med (1971) 0.85
High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid. J Med Chem (1987) 0.85
Highly efficient endonucleolytic cleavage of RNA by a Cys(2)His(2) zinc-finger peptide. Proc Natl Acad Sci U S A (1999) 0.85
Differential effects of aspirin and dexamethasone on phospholipase A2 and C activities and arachidonic acid release from endothelial cells in response to bradykinin and leukotriene D4. Prostaglandins (1986) 0.85
Solubilization of rat liver vasopressin receptors as a complex with a guanine-nucleotide-binding protein and phosphoinositide-specific phospholipase C. Biochem J (1989) 0.85
Leukotriene B4 induces formation of inositol phosphates in rat peritoneal polymorphonuclear leukocytes. Mol Pharmacol (1986) 0.84